Loading
PS
Prim, S.A. Stock: price and insider trades · Spain
No insider purchase over the last 90 days. The latest was filed 02 Dec 2025.
Prim, S.A.: what insiders have been doing
This page follows insider dealings at Prim, S.A. as filed with CNMV, a company from the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Prim, S.A. logged 1 filing by 1 insider.
Only purchases show up on the open market, 1 purchase in all worth €308k, filed by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 chief executive. Biggest ticket of the year: €308k, bought by Mendibea 2002, S.L. and made public on 2 December 2025 (0.14% of market cap).
The clock since the last published purchase (2 December 2025) now reads 320 days.
Compared with its exchange (102 companies, median 7 filings), a count of 1 filing is below the norm. Since 2023, the database holds 3 purchases and no sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from CNMV. Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€1M
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMendibea 2002, S.L.1 buy
Since the insiders bought
- +0.4%Entry €13.70 · Close at T+90 €13.75
- +0.0%Entry €10.15 · Close at T+365 €10.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,884 of 24,161 companies
72.2
score / 100
Value77
Quality68
FCF yld8.0%
Earn yld7.3%
EV/EBITDA7.1x
ROE9.6%
Gross mgn50%
Net mgn6.6%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€13.35
Analyst consensus
1 analysts1.00/5
€16.75Target €16.75(+25%)€16.75
Income statement
Revenue€251.8M
Gross profit€127.0M50% margin
EBITDA€33.9M13% margin
Net income€16.7M5.2% margin
Valuation
PER (trailing)17.3x
PER (forward)10.1x
P/Book1.7x
Beta0.49
Balance sheet & cash
Market cap€227.0M
Total debt€15.5M
Free Cash Flow€18.1M
Debt / Equity14%
Profitability & ownership
ROE9.6%
ROA5.2%
% insiders59.8%
% institutions12.2%
Last declaration on 2 December 2025
Declarations3 total
23,534 shares@ €13.100.14% mcap36.0% of flowShareXMADISIN ES0170884417CNMV:2025146247
Canonical exit: 26 Feb 2026 (T+90)
49,099 shares@ €11.160.25% mcap64.0% of flowShareXMADISIN ES0170884417CNMV:2023121102
Canonical exit: 7 Jan 2024 (T+90)
28,862 shares@ €10.350.14% mcap100.0% of flowShareBMEXISIN ES0170884417CNMV:2023059228
Canonical exit: 1 Aug 2023 (T+90)
3 of 3 declarations
About Prim, S.A.
Prim, S.A. is a company listed on the XMAD market, specializing in the health and pharmaceutical sector. It focuses on the development and distribution of pharmaceutical products and health solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
